Knut Elbers
Project Manager @ Boehringer Ingelheim Venture Fund
Frankfurt, Germany
Knut Elbers is a Series A investor at Boehringer Ingelheim Venture Fund in Frankfurt focused on Biopharma and Life Science. Knut Elbers joined Boehringer Ingelheim as Project Manager.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Knut Elbers invests in
Stages Knut Elbers invests in
Countries Knut Elbers invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biopharma 1 (33%)
- Life Science 1 (33%)
- Neuroscience 1 (33%)
- Therapeutics 1 (33%)
- Biotechnology 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Amal Therapeutics
|
Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology. | $32.6M / Series B / Nov 12, 2018 | |
|
Amal Therapeutics
|
Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology. | $9.5M / Series B / Sep 05, 2017 | |
|
Amal Therapeutics
|
Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology. | $3.1M / Series A / Mar 30, 2016 |
Co-Investors
Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.
Boehringer Ingelheim Venture Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Debbie Lin
Executive Director
|
|||
Martin Heidecker
Managing Director
|
|||
|
Knut Elbers
Project Manager
|
|||
Oliver Reuss
Executive Director and Investment Manager
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Knut Elbers invest in?
Knut Elbers invests primarily in Biopharma, Life Science and Neuroscience startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Knut Elbers?
Public channels for Knut Elbers include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Knut Elbers last invest?
The most recent investment recorded for Knut Elbers closed in Nov 2018. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
